Reply to: Critical evaluation of the ProfiLER-02 study design and outcomes

Olivier Trédan; Marie-Sarah Cabrillac; Sylvie Chabaud; Gwenaëlle Garin; David Pérol; Jean Yves Blay

doi:10.1038/s41591-025-03960-9

Related publications

Letter2014

Study Design and the Drug Development Process—Reply

John P A Ioannidis, Iztok Hozo, Benjamin Djulbegović

Article2020

Tumor Molecular Profiling: Pediatric Results of the ProfiLER Study

Sarah Benezech, Pierre Saintigny, Valéry Attignon, Daniel Pissaloux, Sandrine Paindavoine, Cécile Faure‐Conter, Nadège Corradini, Perrine Marec‐Bérard, Christophe Bergeron, Philippe A. Cassier, Lauriane Eberst, Armelle Dufresne, Qing Wang, Vincent Agrapart, Arnaud de la Fouchardière, David Pérol, Gwenaëlle Garin, Véronique Corset, Leila Ben Abdesselem, Sylvie Chabaud, Olivier Trédan, Jean Yves Blay, Didier Frappaz

Article2023

Large versus limited molecular profiling panel screening program in patients with metastatic sarcoma: An exploratory subgroup analysis from the ProfiLER 02 trial.

Mehdi Brahmi, Olivier Trédan, Nicolas Penel, Christine Chevreau, Christophe Perrin, Nelly Firmin, Emmanuelle Bompas, François Bertucci, Valéry Attignon, Pierre Saintigny, Isabelle Treilleux, Sylvie Chabaud, Gwenaëlle Garin, David Pérol, Jean Yves Blay, Armelle Dufresne

Letter2019

Reply to Comment on: Self-Care Evaluation in COPD

Maria Matarese, Claudio Barbaranelli, Bárbara Riegel

Letter2020

Reply to the Letter to the Editor: “Mixing Apples and Oranges in Assessing Outcomes of Repetitive Transcranial Stimulation Meta-Analyses”

Ali Amad, Renaud Jardri, Chloé Rousseau, Yann Larochelle, John P A Ioannidis, Florian Naudet